Literature DB >> 15482373

Nigella sativa seed extracts enhance glucose-induced insulin release from rat-isolated Langerhans islets.

Halima Rchid1, Hugues Chevassus, Rachid Nmila, Carine Guiral, Pierre Petit, Mustapha Chokaïri, Yves Sauvaire.   

Abstract

Nigella sativa L. 'Black cumin' (Ranunculaceae) is one of the plants commonly used in Moroccan folk medicine for treatment of various ailments including diabetes mellitus. The present study was undertaken to investigate the effect of different N. sativa seed extracts on insulin secretion. Different fractions of the seed were prepared: the defatted fraction (HR II), which was divided into two subfractions: the first (HR III) containing acidic and neutral compounds and the second (HR IV) containing basic compounds. The insulin secretory effects of these extracts were evaluated individually at different concentrations (0.01, 0.1, 1 and 5 mg/mL), in vitro in isolated rat pancreatic islets in the presence of 8.3 mmol/L glucose. The results show that addition of the defatted whole extract or of the basic subfraction of the seed in the incubation medium significantly increased glucose-induced insulin release from the islets. In the case of the acidic and neutral subfraction, the stimulatory effect was observed only for the higher concentration (5 mg/mL). However, a clear concentration-dependent increase in insulin release from isolated pancreatic islets was observed for the basic subfraction. Our data show that the antidiabetic properties of N. sativa seeds may be, at least partly, mediated by stimulated insulin release, and that the basic subfraction largely contributes to this stimulatory effect. Further phytochemical studies are underway in order to isolate the pharmacological compound(s) responsible for the insulinotropic effect of N. sativa seeds.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15482373     DOI: 10.1111/j.1472-8206.2004.00275.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  22 in total

Review 1.  Mitigation of obesity-promoted diseases by Nigella sativa and thymoquinone.

Authors:  Jairam Vanamala; Andrew C Kester; Adam L Heuberger; Lavanya Reddivari
Journal:  Plant Foods Hum Nutr       Date:  2012-06       Impact factor: 3.921

Review 2.  A review of the effects of Nigella sativa L. and its constituent, thymoquinone, in metabolic syndrome.

Authors:  B M Razavi; H Hosseinzadeh
Journal:  J Endocrinol Invest       Date:  2014-08-15       Impact factor: 4.256

Review 3.  Natural antioxidants in the treatment and prevention of diabetic nephropathy; a potential approach that warrants clinical trials.

Authors:  Noori Al-Waili; Hamza Al-Waili; Thia Al-Waili; Khelod Salom
Journal:  Redox Rep       Date:  2017-03-09       Impact factor: 4.412

4.  Thymoquinone, a bioactive component of Nigella sativa, normalizes insulin secretion from pancreatic β-cells under glucose overload via regulation of malonyl-CoA.

Authors:  Joshua P Gray; Delaine Zayasbazan Burgos; Tao Yuan; Navindra Seeram; Rebecca Rebar; Rebecca Follmer; Emma A Heart
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-01-19       Impact factor: 4.310

5.  Effects of Nigella sativa seeds (black cumin) on insulin secretion and lipid profile: A pilot study in healthy volunteers.

Authors:  Sophie Pelegrin; Florence Galtier; Anne Chalançon; Jean-Pierre Gagnol; Anne-Marie Barbanel; Yves Pélissier; Michel Larroque; Samuel Lepape; Marie Faucanié; Isabelle Gabillaud; Pierre Petit; Hugues Chevassus
Journal:  Br J Clin Pharmacol       Date:  2019-05-20       Impact factor: 4.335

6.  Nigella sativa and thymoquinone attenuate oxidative stress and cognitive impairment following cerebral hypoperfusion in rats.

Authors:  Sahar Fanoudi; Mohaddeseh S Alavi; Mahmoud Hosseini; Hamid R Sadeghnia
Journal:  Metab Brain Dis       Date:  2019-04-23       Impact factor: 3.584

7.  Emerging clinical and therapeutic applications of Nigella sativa in gastroenterology.

Authors:  Shailendra Kapoor
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742

8.  Nigella sativa: A Potential Antiosteoporotic Agent.

Authors:  Ahmad Nazrun Shuid; Norazlina Mohamed; Isa Naina Mohamed; Faizah Othman; Farihah Suhaimi; Elvy Suhana Mohd Ramli; Norliza Muhammad; Ima Nirwana Soelaiman
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-03       Impact factor: 2.629

9.  The In Vivo Antidiabetic Activity of Nigella sativa Is Mediated through Activation of the AMPK Pathway and Increased Muscle Glut4 Content.

Authors:  Ali Benhaddou-Andaloussi; Louis Martineau; Tri Vuong; Bouchra Meddah; Padma Madiraju; Abdellatif Settaf; Pierre S Haddad
Journal:  Evid Based Complement Alternat Med       Date:  2011-04-14       Impact factor: 2.629

Review 10.  Nigella sativa in controlling Type 2 diabetes, cardiovascular, and rheumatoid arthritis diseases: Molecular aspects.

Authors:  Vahid Hadi; Naseh Pahlavani; Mahsa Malekahmadi; Elyas Nattagh-Eshtivani; Jamshid Gholizadeh Navashenaq; Saeid Hadi; Gordon A Ferns; Majid Ghayour-Mobarhan; Gholamreza Askari; Abdolreza Norouzy
Journal:  J Res Med Sci       Date:  2021-03-31       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.